Top Qs
Timeline
Chat
Perspective
Dimethyltryptamine/harmine
Pharmaceutical compound From Wikipedia, the free encyclopedia
Remove ads
Dimethyltryptamine/harmine (developmental code name RE01 or RE-01) is a combination of dimethyltryptamine (DMT), a tryptamine serotonin receptor agonist and serotonergic psychedelic, and harmine, a β-carboline reversible inhibitor of monoamine oxidase A (RIMA), which is under development for the treatment of mood disorders.[1][2][3]
Remove ads
It is a form of pharmahuasca (pharmaceutical ayahuasca), in which DMT is combined with a synthetically produced monoamine oxidase inhibitor (MAOI) as opposed to a plant-derived form such as Banisteriopsis caapi as in ayahuasca.[4] Harmine, acting as a RIMA, inhibits the metabolism of DMT, in turn greatly potentiating DMT and allowing it to become orally active.[5][6][7]
The combination is being developed by Reconnect Labs.[1][2][3] As of August 2023, it is in phase 1 clinical trials.[1][2][3]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads